August 2021 Test Bulletin

August 9, 2021

Alverno Laboratories issued updates relevant to healthcare providers, including an NT proBNP assay update for monitoring congestive heart failure patients taking Entresto®, reflecting variations in values and emphasizing clinical correlation, a reflexive lung cancer panel replacing the current ARUP Lung Cancer with KRAS, now including reflex testing to ALK and ROS1 if EGFR and KRAS testing show wildtype status, and an update to Drugs of Abuse panels, lowering the Opiates assay cutoff level to 300ng/mL for improved clinical testing suitability. These updates aim to enhance diagnostic accuracy and clinical utility, ensuring optimal patient care.